Agenus’ Brain Cancer Vaccine Program Named a "Top Project to Watch" by Elsevier Business Intelligence
November 18 2013 - 7:00AM
Business Wire
- Agenus to present at 2013 Therapeutic
Area Partnerships Conference
Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines
for cancer and infectious diseases, today announced that its
Prophage Series (HSPPC-96) vaccine program for the treatment of
brain cancer was selected as a 2013 Top Project to Watch in
oncology. This selection was made through Elsevier Business
Intelligence's panel of independent experts who screen hundreds of
programs and weigh their potential as future products.
The company also announced that Jennifer S. Buell, Ph.D., Vice
President of Clinical Research and Operations, will present an
overview of the ongoing Prophage Series vaccine Phase 2 program in
newly diagnosed and recurrent glioblastoma multiforme (GBM) at the
2013 Therapeutic Area Partnerships Conference on Tuesday, November
19, 2013 at 1:10 pm EST at the Hyatt Regency in Boston, MA.
A recent analysis from the Phase 2 trial in patients with newly
diagnosed GBM treated with Prophage Series in combination with the
current standard of care (radiation and temozolomide) showed an
almost 18 month median progression free survival, which represents
a 160% increase versus current standard of care alone.1 Median
overall survival (OS), the primary endpoint of the trial, is 23.3
months and remains durable in patients treated with Prophage Series
vaccine versus the standard of care alone, which is 14.6 months.1
Patients continue to be followed for survival. Based on these
findings, Agenus plans to hold an end of Phase 2 meeting with the
US Food and Drug Administration to discuss a Phase 3 trial that, if
initiated and successful, could potentially lead to marketing
approval of the Prophage Series vaccine as a treatment for patients
with newly diagnosed GBM.
In addition to the Phase 2 newly diagnosed GBM trial, the
National Cancer Institute (NCI) is supporting a study of the
Prophage Series vaccine in a large, randomized Phase 2 trial in
combination with bevacizumab (Avastin®) in patients with surgically
resectable recurrent GBM. The study is being sponsored by the
Alliance for Clinical Trials in Oncology (ALLIANCE), a cooperative
group of the NCI. This trial is the largest brain tumor trial ever
funded by the NCI and the largest vaccine study ever conducted with
Avastin.
The ALLIANCE trial is investigating the potential benefits of
treatment with a combination of Prophage Series and bevacizumab in
a three-arm study of approximately 222 patients with surgically
resectable recurrent GBM using a primary endpoint of OS. The study
will compare efficacy of the Prophage Series vaccine administered
with bevacizumab either concomitantly or at progression, versus
treatment with bevacizumab alone. For additional information about
the ALLIANCE trial visit ClinicalTrials.gov using Identifier
NCT01814813.
About Prophage Series Vaccines
Derived from each individual’s tumor, Prophage Series
therapeutic vaccines contain the ‘antigenic fingerprint’ of the
patient’s particular cancer and are designed to direct the body’s
immune system to specifically target and destroy cancer cells
bearing this fingerprint. Prophage Series vaccines, based on
Agenus’ heat shock protein platform technology, are intended to
leave healthy tissue unaffected and limit the debilitating side
effects typically associated with traditional cancer treatments
such as chemotherapy and radiation therapy.
Each patient’s cancer is unique. Random mutations and tens of
thousands of genes mean even within the same type of cancer, no two
individuals’ cancers are biologically the same. Taking these
factors into account, the Prophage Series vaccines are developed
from the best biological representation of a patient’s cancer and
created individually for each patient from their own tumor.
The Prophage Series vaccines are currently being studied in both
newly diagnosed and recurrent GBM. GBM is the most aggressive
primary malignant brain tumor and accounts for the majority of
diagnoses of malignant cancers of the brain.
For more information about Prophage Series vaccines and Agenus’
heat shock protein platform, please visit
http://agenusbio.com/science/prophage.php.
About Agenus
Agenus Inc. is a biotechnology company developing treatments for
cancers and infectious diseases. The company has multiple
immunotherapeutic products based on strong technology platforms
that are advancing through the clinic. Agenus’ technology is
further validated through partnerships with major pharmaceutical
companies, with several product candidates in late-stage clinical
trials with corporate partners. For more information, please visit
www.agenusbio.com.
About Elsevier Business Intelligence and the Therapeutic Area
Partnerships Conference
Elsevier Business Intelligence provides business intelligence on
regulatory, business and reimbursement issues that are vital to the
healthcare industry. Through a range of products including
publications, conferences, databases and reports, Elsevier Business
Intelligence places biopharma and medical device professionals, and
those who focus on these industries, at the forefront of knowledge,
by providing a combination of news and information together with
penetrating insight and analysis.
Organized by Elsevier Business Intelligence, the 2013
Therapeutic Area Partnerships (TAP) conference is designed to bring
together biopharmaceutical industry decision makers to assess the
most promising drug programs available for partnering in the
following therapeutic areas: oncology, cardiovascular/metabolic
diseases, neuroscience, infectious diseases,
anti-inflammatory/autoimmune diseases and advanced therapies. For
more information, please visit the conference website at
http://www.elsevierbi.com/mkt/Conf/TAP2013/PresentingCos.
Forward-Looking Statement
This press release contains forward-looking statements,
including statements regarding clinical trial activities, the
publication of data, and the potential application of the Company’s
technologies and product candidates in the prevention and treatment
of diseases. These forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of our
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission for the period ended September 30, 2013. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this document, and Agenus
undertakes no obligation to update or revise the statements. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement. Agenus’ business is subject
to substantial risks and uncertainties, including those identified
above. When evaluating Agenus’ business and securities, investors
should give careful consideration to these risks and
uncertainties.
References
1. Stupp, R., et al., Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. NEngl J Med, 2005. 352(10): p.
987-96.
Media and Investor:Jonae R. Barnes, 617-818-2985Vice
PresidentInvestor Relations and Corporate
Communicationsjonae.barnes@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024